ALK and squamous cell carcinoma: At present, it is considered that the efficacy of neoadjuvant immunotherapy is related to the expression of PD-L1 while pathological tumor type (CheckMate 816 showed that squamous cell carcinoma has better neoadjuvant therapy efficacy than adenocarcinoma), EGFR/ALK state (the effectiveness of neoadjuvant immunotherapy in patients with EGFR/ALK mutation is poor), and more markers for predicting the treatment effect are still being explored (32, 34, 39).